Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.
Jeffrey Howard Lipton
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; CSL; Novartis
Brian Leber
Honoraria - Novartis
Expert Testimony - Novartis
Carmino De Souza
Consultant or Advisory Role - Novartis
Pedro E Dorlhiac-Llacer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Juan Luis Steegmann
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis
Agnes Guerci-Bresler
No relevant relationships to disclose
Anthony P. Schwarer
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Novartis
Francisco Cervantes
Consultant or Advisory Role - Novartis
Honoraria - Novartis
John Reynolds
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Research Funding - NHMRC Austrailia; Victorian Cancer Agency Austrailia
LaTonya R Collins
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tomasz K. Szczudlo
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nelson Spector
Consultant or Advisory Role - Novartis
Research Funding - Novartis